Press release
Dermatomyositis Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Dermatomyositis Clinical Trials
(Albany, United States) As per DelveInsight's assessment, globally, Dermatomyositis pipeline constitutes 10+ key companies continuously working towards developing 10+ Dermatomyositis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Dermatomyositis Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dermatomyositis Market.
The Dermatomyositis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ Dermatomyositis Pipeline Outlook - https://www.delveinsight.com/report-store/dermatomyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Dermatomyositis Pipeline Report:
• Dermatomyositis Companies across the globe are diligently working toward developing novel Dermatomyositis treatment therapies with a considerable amount of success over the years.
• Dermatomyositis companies working in the treatment market are Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals, others are developing therapies for the Dermatomyositis treatment.
• Emerging Dermatomyositis therapies such as EFG PH20, KZR-616, and others are expected to have a significant impact on the Dermatomyositis market in the coming years.
• In June 2024, Priovant Therapeutics, Inc announced results of a A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults With Dermatomyositis
• In June 2024, Galapagos announced results of a Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GLPG3667 Once Daily for 24 Weeks in Adult Subjects With Dermatomyositis
• In July 2024, CSL Behring announced a Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults With Dermatomyositis (DM) - The RECLAIIM Study
• In June 2024, argenx announced results of a Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart in Adults With Dermatomyositis
• In June 2024, AstraZeneca announced results of a Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Dermatomyositis Overview
Dermatomyositis is a rare inflammatory disease characterized by muscle weakness and a distinctive skin rash. It is considered an autoimmune disorder, where the body's immune system mistakenly attacks its own tissues. The condition can affect both adults and children, with women being more frequently affected than men. The hallmark symptoms of dermatomyositis include muscle weakness, primarily in the shoulders, hips, and thighs, along with a violet-colored or dusky red rash on the face, eyelids, knuckles, elbows, knees, chest, and back.
Muscle weakness in dermatomyositis can lead to difficulty with everyday activities such as climbing stairs, rising from a seated position, or lifting objects. The skin rash often precedes the muscle weakness and can be exacerbated by sun exposure. Additional symptoms may include fatigue, difficulty swallowing, and lung problems. The exact cause of dermatomyositis is unknown, but genetic and environmental factors are believed to play a role.
Diagnosis involves a combination of clinical evaluation, blood tests for muscle enzymes, electromyography, muscle biopsy, and imaging studies. Treatment typically includes corticosteroids and immunosuppressive drugs to reduce inflammation and suppress the immune system. Physical therapy is also important to maintain muscle strength and function. Early diagnosis and treatment are crucial in managing symptoms and improving the quality of life for those affected by dermatomyositis.
Get a Free Sample PDF Report to know more about Dermatomyositis Pipeline Therapeutic Assessment- Dermatomyositis Drugs in Pipeline - https://www.delveinsight.com/sample-request/dermatomyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Dermatomyositis Route of Administration
Dermatomyositis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
Dermatomyositis Molecule Type
Dermatomyositis Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Dermatomyositis Pipeline Therapeutics Assessment
• Dermatomyositis Assessment by Product Type
• Dermatomyositis By Stage and Product Type
• Dermatomyositis Assessment by Route of Administration
• Dermatomyositis By Stage and Route of Administration
• Dermatomyositis Assessment by Molecule Type
• Dermatomyositis by Stage and Molecule Type
DelveInsight's Dermatomyositis Report covers around 10+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Dermatomyositis product details are provided in the report. Download the Dermatomyositis pipeline report to learn more about the emerging Dermatomyositis therapies- Dermatomyositis Therapeutics Market - https://www.delveinsight.com/report-store/dermatomyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Dermatomyositis Pipeline Analysis:
The Dermatomyositis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Dermatomyositis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dermatomyositis Treatment.
• Dermatomyositis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dermatomyositis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dermatomyositis market.
Download Sample PDF Report to know more about Dermatomyositis drugs and therapies- Dermatomyositis Clinical trials and FDA Approvals - https://www.delveinsight.com/sample-request/dermatomyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of Dermatomyositis Pipeline Drug Insight
• Coverage: Global
• Key Dermatomyositis Companies: Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals, others.
• Key Dermatomyositis Therapies: EFG PH20, KZR-616, and others.
• Dermatomyositis Therapeutic Assessment: Dermatomyositis current marketed and Dermatomyositis emerging therapies
• Dermatomyositis Market Dynamics: Dermatomyositis market drivers and Dermatomyositis market barriers
Request for Sample PDF Report for Dermatomyositis Pipeline Assessment and clinical trials - Dermatomyositis Drugs and Therapies - https://www.delveinsight.com/sample-request/dermatomyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Dermatomyositis Report Introduction
2. Dermatomyositis Executive Summary
3. Dermatomyositis Overview
4. Dermatomyositis- Analytical Perspective In-depth Commercial Assessment
5. Dermatomyositis Pipeline Therapeutics
6. Dermatomyositis Late Stage Products (Phase II/III)
7. Dermatomyositis Mid Stage Products (Phase II)
8. Dermatomyositis Early Stage Products (Phase I)
9. Dermatomyositis Preclinical Stage Products
10. Dermatomyositis Therapeutics Assessment
11. Dermatomyositis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Dermatomyositis Companies
14. Dermatomyositis Key Products
15. Dermatomyositis Unmet Needs
16 . Dermatomyositis Market Drivers and Barriers
17. Dermatomyositis Future Perspectives and Conclusion
18. Dermatomyositis Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market-forecast
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Xerostomia Market: https://www.delveinsight.com/whitepaper-newsletter/xerostomia-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/osteoarthritis-market
• Brain/cranial Implants Market: https://www.delveinsight.com/report-store/brain-implants-market-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Pharma Competitive Intelligence: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Surgical Site Infections Market: https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiac Resynchronization Therapy Device Market: https://www.delveinsight.com/report-store/cardiac-resynchronization-therapy-market
• Central Retinal Venous Occulsion Market: https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
• Cerebral Vein Thrombosis Market: https://www.delveinsight.com/report-store/cerebral-vein-thrombosis-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Febrile Neutropenia Market: https://www.delveinsight.com/report-store/febrile-neutropenia-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage
Case study: https://www.delveinsight.com/case-study/go-to-market-strategy
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dermatomyositis Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight here
News-ID: 3745872 • Views: …
More Releases from DelveInsight Business Research
Global Pharmaceutical Cartridges Market to grow at a CAGR of 7.39% to reach USD …
According to DelveInsight's analysis, The growth of the pharmaceutical cartridges market is largely fueled by the increasing prevalence of chronic diseases that require long-term and consistent medication use. Moreover, the rising trend of self-administered treatments and the growing preference for home-based healthcare are major contributors to market expansion. Technological advancements in drug delivery systems have further supported this growth by enhancing patient convenience, improving dosage precision, and promoting better treatment…
Global Nucleic Acid Amplification Testing Market to grow at a CAGR of 8.13% by 2 …
According to DelveInsight's analysis, The growing demand for Nucleic Acid Amplification Testing (NAAT) is primarily driven by the increasing prevalence of infectious and genetic diseases. Additionally, the rising incidence of cancer and the expanding R&D efforts by major industry players are further fueling market growth. Together, these factors are expected to support a strong upward trajectory for the NAAT market throughout the forecast period from 2025 to 2032.
DelveInsight's "Nucleic Acid…
Global Cardiac Mapping System Market to grow at a CAGR of 8.37% by 2032, Evaluat …
According to DelveInsight's analysis, The growing incidence of cardiac arrhythmias, including atrial fibrillation and ventricular tachycardia, is driving the expansion of the cardiac mapping system market. These systems play a crucial role in the early detection and management of such conditions by providing real-time visualization of the heart's electrical activity, thereby reducing the risk of severe complications like stroke and heart failure. Moreover, the rising adoption of minimally invasive procedures,…
Global Graft Preparation System Market to grow at a CAGR of 4.17% to reach USD 3 …
According to DelveInsight's analysis, The demand for graft preparation systems is experiencing notable growth, primarily driven by the rising incidence of bone disorders and skin-related conditions. Moreover, the increasing number of surgical procedures worldwide, coupled with expanding R&D initiatives and strategic collaborations among leading market players, is further fueling market expansion. Together, these factors are expected to create a strong growth outlook for the graft preparation system market during the…
More Releases for Dermatomyositis
Dermatomyositis market expected to reach USD 1.2 billion by 2034
Dermatomyositis is a rare, chronic autoimmune condition characterized by muscle inflammation and distinctive skin rashes. The disease impacts both adults and children, with complications that include interstitial lung disease and increased cancer risk. Despite its rarity, dermatomyositis places a significant burden on patients due to disability, reduced quality of life, and high treatment costs.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71381
In recent years, the dermatomyositis market has seen…
Dermatomyositis Market to Witness Promising Upswing by 2034, DelveInsight Foreca …
DelveInsight's "Dermatomyositis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Dermatomyositis, historical and forecasted epidemiology as well as the Dermatomyositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Dermatomyositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dermatomyositis Market Forecast
https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Dermatomyositis…
Dermatomyositis (DM) Market Emerging Trends and Growth Prospects 2034
Introduction
Dermatomyositis (DM) is a rare, chronic autoimmune inflammatory myopathy characterized by muscle weakness and distinctive skin rashes. It affects both adults and children and is associated with complications such as interstitial lung disease, malignancies, and cardiovascular involvement. The disease significantly reduces patient quality of life and requires long-term medical care.
Historically treated with corticosteroids and immunosuppressants, the market is now evolving with biologics, monoclonal antibodies, and targeted immunotherapies. Increasing global awareness…
Dermatomyositis Treatment Market Growth Accelerates: Strategic Forecast Predicts …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Dermatomyositis Treatment Industry Market Size Be by 2025?
The market for dermatomyositis treatment has seen significant expansion in the past few years. It is projected to escalate from $0.85 billion in 2024 to $0.91 billion in 2025, representing a compound annual growth rate (CAGR) of 7.2%.…
Dermatomyositis Market - Defying the challenges of dermatomyositis: choose our t …
Newark, New Castle, USA: The "Dermatomyositis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Dermatomyositis Market: https://www.growthplusreports.com/report/dermatomyositis-market/8675
This latest report researches the industry structure, sales, revenue, price and…
Dermatomyositis Market Size, Analysis, Share, Research, Business Growth and Fore …
Dermatomyositis Market 2021 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global Dermatomyositis industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2021 to 2031 time period. It presents a close overview of the…
